Financial Management and Accountability Determination 2005/14 — Human Pituitary Hormones Special Account Variation and Abolition 2005

I, NICK MINCHIN, Minister for Finance and Administration, make this Determination under subsection 20 (2) and 20 (3) of the Financial Management and Accountability Act 1997.

Dated 7 June 2005

Nick Minchin

Minister for Finance and Administration

 

1 Name of Determination

  This Determination is the Financial Management and Accountability Determination 2005/14 — Human Pituitary Hormones Special Account Variation and Abolition 2005.

2 Commencement

  This Determination commences at the time at which subsection 22 (4) of the FMA Act is complied with.

Note   This Determination takes effect in accordance with section 22 of the FMA Act. The Parliament must consider the Determination before it can take effect, and either House may pass a resolution disallowing the Determination. If neither House passes such a resolution, the Determination takes effect on the day immediately after the last day upon which such a resolution could have been passed.

3 Variation of Initial Determination to Establish Components of the Reserved Money Fund

  Schedule 1 varies the Initial Determination to Establish Components of the Reserved Money Fund, which established among others, the Human Pituitary Hormones Account.

4 Abolition of Human Pituitary Hormones Account

  The Human Pituitary Hormones Account is abolished with effect from the time at which:

 (a) the balance of the appropriation for the Account reaches zero; and

 (b) the variation made under section 3 has taken effect.

Schedule 1 Variation

(section 3)

[1] Determination, attachment

omit

For expenditure through grants and other payments on:

 (a) counselling and support services to recipients of pituitary-derived hormones and their families;

 (b) medical and other care to people treated with pituitary-derived hormones should they contract Creutzfeldt-Jakob disease as a result of the treatment.

insert

(a) For expenditure through grants and other payments on:

 (i) counselling and support services to recipients of pituitary-derived hormones and their families; and

 (ii) medical and other care to people treated with pituitary-derived hormones if they contract Creutzfeldt-Jakob disease as a result of the treatment; and

(b) To credit amounts to the Human Pituitary Hormones Special Account.